InspireMD (NYSE:NSPR) Director Scott Ward Buys 73,255 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) Director Scott Ward acquired 73,255 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was purchased at an average price of $1.15 per share, for a total transaction of $84,243.25. Following the completion of the purchase, the director directly owned 237,096 shares in the company, valued at $272,660.40. This trade represents a 44.71% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

InspireMD Stock Down 0.9%

Shares of NYSE:NSPR opened at $1.15 on Friday. The firm has a market capitalization of $53.93 million, a PE ratio of -1.53 and a beta of 0.82. InspireMD, Inc. has a twelve month low of $1.02 and a twelve month high of $2.93. The company has a 50-day moving average price of $1.51 and a two-hundred day moving average price of $1.75.

Institutional Investors Weigh In On InspireMD

A number of institutional investors and hedge funds have recently modified their holdings of the company. Rosalind Advisors Inc. boosted its position in shares of InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock valued at $9,413,000 after acquiring an additional 1,616,644 shares during the period. Nantahala Capital Management LLC grew its stake in InspireMD by 45.7% during the third quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock valued at $8,137,000 after acquiring an additional 1,058,467 shares in the last quarter. Aberdeen Group plc increased its holdings in InspireMD by 27.9% during the 4th quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock worth $5,649,000 after acquiring an additional 692,247 shares during the period. Orbimed Advisors LLC increased its holdings in InspireMD by 46.9% during the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after acquiring an additional 1,000,000 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its stake in InspireMD by 97.6% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock worth $5,882,000 after purchasing an additional 1,205,328 shares in the last quarter. 44.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on NSPR. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a report on Tuesday. Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Lake Street Capital set a $4.00 target price on InspireMD in a research report on Monday. Finally, Maxim Group assumed coverage on InspireMD in a report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price target for the company. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, InspireMD presently has an average rating of “Buy” and a consensus price target of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.